Pharmstandard
Pharmstandard develops drugs for diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders.
Business Model:
Revenue: $1B
Employees: 5,001-10,000
Rankings
Industries / Tags:
Detailed Pharmstandard Information
Geographic Data
Address: Likhachevskiy pr-d, 5
City: Dolgoprudnyy
State: moscow oblast
Zip: 141701
Country: RU
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Metrics
9,059,110Website Global Rank
219Website Monthly Traffic
Twitter Followers
Description
Pharmstandard develops drugs for diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders.
Contact Phone:
Contact Email:
Pharmstandard went public on 5/4/2007 on the Moscow Exchange
Listed Exchange:
Moscow Exchange
IPO Date:
5/4/2007
Ticker Symbol:
PHST
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2015 | enGene | Series B | 0 |
| 12/2017 | Viriom | Convertible Note | 12.5M |
| 7/2016 | TransMedics | Private Equity Round | 0 |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 3/2016 | Argos Therapeutics | Post-IPO Equity | 0 |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 12/2017 | TearSolutions | Series B | 0 |
| 8/2016 | Avelas Biosciences | Series C | 0 |
| 3/2019 | TearSolutions | Series B | 0 |
| 5/2014 | Proteon Therapeutics | Series D | 0 |
| 9/2013 | Protagonist Therapeutics | Series B | 4M |
| 8/2013 | Argos Therapeutics | Series E | 0 |
| 2/2017 | Genotek | Seed Round | 0 |
| 3/2019 | TearSolutions | Series B | 0 |
| 12/2017 | TearSolutions | Series B | 0 |
| 12/2017 | Viriom | Convertible Note | 0 |
| 2/2017 | Genotek | Seed Round | 0 |
| 8/2016 | Avelas Biosciences | Series C | 0 |
| 7/2016 | TransMedics | Private Equity Round | 0 |
| 3/2016 | Argos Therapeutics | Post-IPO Equity | 0 |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 1/2015 | enGene | Series B | 0 |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 7/2018 | PET-Technology |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
